Adakitug by Bristol-Myers Squibb for Hormone-Sensitive Prostate Cancer: Likelihood of Approval

Adakitug is under clinical development by Bristol-Myers Squibb and currently in Phase II for Hormone-Sensitive Prostate Cancer.

FILAMENT HEALTH ANNOUNCES UPSIZING AND CLOSING OF $2,500,000 NON-BROKERED PRIVATE PLACEMENT FINANCING – Psychedelic Alpha

Financing led by psychedelic investment fund Negev Capital VANCOUVER, BC, July 24, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or

July 24, 2023

Cybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic Therapeutics | Psychedelic Invest

–Combined portfolios create the industry’s largest, most advanced, well-protected deuterated DMT program – – Combination creates the largest intellectual property portfolio in the psychedelic drug

October 23, 2023

Illumina plans layoffs, closure of San Diego facility in push to save $100M a year

Dive Brief: Illumina is laying off staff and closing a facility in San Diego as part of its push to cut its annual spending by

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.